Management of Suspected Endogenous Endophthalmitis

A proper workup and timely interventions can help to limit vision loss.

By Theodore Leng, MD, MS
 

As retinal specialists, we may be called upon to consult on inpatients with decreased vision. At the bedside, a thorough history and ocular exam should be performed with special sensitivity to the possibility of endogenous endophthalmitis. Although it is a rare condition (the reported incidence is about 5 per 100 000 hospitalized patients1), if not promptly diagnosed and treated, the result may be permanent vision loss.

PATIENT HISTORY

The history should focus on the reason for hospital admission, the presence of any positive blood cultures, and evidence of immune suppression. Although a history of HIV/AIDS, organ transplantation, leukemia, lymphoma, and other cancers are the usual red flags for immunosuppression, other potential risk factors for endogenous endophthalmitis are the presence of diabetes mellitus, indwelling catheters, recent surgery, a history of IV drug use, pregnancy, a history of gynecologic procedures, and parenteral nutrition.1-5

CLINICAL EXAMINATION

The examination should concentrate on checking for the presence of intraocular inflammation. Although it is very difficult to check for anterior chamber cell in a bed-bound patient, the posterior pole is where one should focus when endophthalmitis is suspected. Immunosuppressed patients often have difficulty mounting an inflammatory reaction, so vitritis (as well as hypopyon) may be minimal. In these cases, the most important features to identify would be the presence of whitish choroidal or chorioretinal lesions and white, plumate vitreous globules (sometimes termed “puff balls”). Be aware that in this patient population it is often difficult to distinguish between infection and infiltration (such as a neoplastic process) or the sequelae of pancytopenia.

Watch video on Eyetube.net

If a choroidal or vitreous lesion is detected and endogenous endophthalmitis is a concern, systemic evaluation is imperative to determine a primary site of infection. Inherent in its definition, endogenous (or “metastatic”) endophthalmitis arises after hematogenous spread circumvents or overwhelms the blood brain-barrier.6 For this reason, blood cultures are recommended, although their reported sensitivity varies. Some studies have reported positive cultures in as many as 75% of patients,5 while others cite no identified primary infectious focus in more than 40% of cases.7

Watch video on Eyetube.net

DIAGNOSTIC TESTS/TREATMENTS

The infectious agents underlying endogenous endophthalmitis are bacterial in approximately half of the cases and fungal in the remaining half.7 Although the relative proportion of cases any given infectious agent causes varies widely with region, in the United States bacterial endophthalmitis is caused mainly by Streptococcus (20%), Staphylococcus (30-50%), and Escherichia coli (30%).8 In contrast, Klebsiella pneumoniae is the primary cause in Asia, accounting for nearly 80% of cases.2,9 The majority of fungal cases are caused by Candida, which accounts for approximately 60% of cases. Following this, Aspergillus is the second most common cause.10

A vitreous tap and injection should be performed with antibacterial or antifungal agents (depending on the suspected organisms) if the vitreous is involved. Generally, vancomycin (1 mg) can be used to cover gram-positive organisms, ceftazidime (2.25 mg) for gram negatives, and either amphotericin B (5 mcg) or voriconazole (0.1 mg) for suspected fungal organisms. Avoid intravitreal steroids if a fungal cause is on your differential.

Consultation with the infectious disease service should be obtained and systemic antibiotics strongly considered. Daily fundus exams should be performed. If the patient’s clinical course worsens, a diagnostic vitrectomy should be considered. If indicated, obtain an undiluted specimen for staining and culture. Be sure to also send the cassette to the lab. Repeat administration of antibacterial and antifungal agents should be given at the conclusion of the vitrectomy.

Endogenous endophthalmitis can be a vision-threatening condition. A proper workup and timely interventions can help to limit vision loss.

Theodore Leng, MD, MS, is a Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford in Palo Alto, CA. He may be reached at tedleng@stanford.edu. Read more on his eye health blog: VisionMD.org.

Jorge A. Fortun, MD, is an Assistant Professor of Ophthalmology at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. Dr. Fortun is Co-Section Editor of the VBS page in Retina Today and on Eyetube.net. He may be reached via email at jfortun@med.miami.edu.

Rohit Ross Lakhanpal, MD, FACS, is a Partner at Eye Consultants of Maryland and is the Vice President of the Vit- Buckle Society. Dr. Lakhanpal is Co-Section Editor of the VBS page in Retina Today and on Eyetube.net. He may be reached at retinaross@gmail.com or at GVoice #443-684-2020.

  1. Fan JC, Niederer RL, von Lany H, Polkinghorne PJ. Infectious endophthalmitis: clinical features, management and visual outcomes. Clin Experiment Ophthalmol. 2008;36(7):631-636.
  2. Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):403-423.
  3. Michelson JB, Friedlaender MH. Endophthalmitis of drug abuse. Int Ophthalmol Clin. 1987;27(2):120-126.
  4. Ness T, Pelz K, Hansen LL. Endogenous endophthalmitis: microorganisms, disposition and prognosis. Acta Ophthalmol Scand. 2007;85(8):852-856.
  5. Okada AA, Johnson RP, Liles WC, et al. Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology. 1994;101(5):832-838.
  6. Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology. 2000;107(8):148314-91.
  7. Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore). 2003;82(2):97-105.
  8. Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19(3):227-234.
  9. Smith SR, Kroll AJ, Lou PL, Ryan EA. Endogenous bacterial and fungal endophthalmitis. Int Ophthalmol Clin. 2007;47(2):1731-83.
  10. Keynan Y, Finkelman Y, Lagace-Wiens P. The microbiology of endophthalmitis: global trends and a local perspective. Eur J Clin Microbiol Infect Dis. 2012;31(11):2879-2886.
 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.